Monday, December 05, 2016 9:04:11 AM
Spectrum Pharmaceuticals Highlights Five Abstracts on ROLONTIS™ (eflapegrastim) and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016 December 5, 2016
HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its products at the San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas, from December 6-10, 2016.
For more information about the SABCS meeting and for a complete list of abstracts, please refer to the conference website at http://www.abstracts2view.com/sabcs/.
The following are key ROLONTISTM (eflapegrastim) related abstracts being presented at the SABCS meeting:
Abstract # Type Title First Author Date/Time
Location: Hall 1
OT1-01-11 Poster Randomized phase 3 study of a novel, long-acting G-CSF (eflapegrastim) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study)
Schwartzberg Wednesday, Dec 7
5:00 PM
P5-11-09 Poster Sustained efficacy of eflapegrastim in breast cancer patients in a phase 2, open-label, dose-ranging study
Vacirca Friday, Dec 9
5:00 PM
P5-11-07 Poster Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen
Vacirca Friday, Dec 9
5:00 PM
P5-11-08 Poster Immunogenicity of eflapegrastim in a Phase 2 Open-Label Dose-Ranging Study of eflapegrastim in Breast Cancer Patients Receiving TC Regimen
Vacirca Friday, Dec 9
5:00 PM
The following key poziotinib related abstract will be presented at the SABCS meeting:
Abstract # Type Title First Author Date/Time
Location: Hall 1
OT1-02-10 Poster A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM